Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TYK2 | P29597 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666324 | 1.00 | NPC1 (0.52) | NPC1RAB9AALDH1A1TYK2KMT2A | |
| SCHEMBL32677813 | 0.90 | TYK2 (0.43) | NPC1RAB9AALDH1A1TYK2KMT2A | |
| SCHEMBL31017468 | 0.84 | MAP4K1 (0.47) | DEGS1 | |
| SCHEMBL31017485 | 0.84 | MAP4K1 (0.47) | DEGS1 | |
| SCHEMBL31017395 | 0.84 | MAP4K1 (0.47) | DEGS1 | |
| SCHEMBL31287989 | 0.83 | MAP4K1 (0.40) | NPC1RAB9AALDH1A1TYK2KMT2A | |
| SCHEMBL31287946 | 0.83 | MAP4K1 (0.40) | NPC1RAB9AALDH1A1TYK2KMT2A | |
| SCHEMBL32677838 | 0.82 | HCAR3 (0.49) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL30549436 | 0.81 | HCAR3 (0.45) | L3MBTL1 | |
| SCHEMBL29686685 | 0.81 | KMT2A (0.54) | NPC1RAB9AALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023213308-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 苏州隆博泰药业有限公司 | 2023-11-09 | — | — | WO | claimed |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LTD (GB) | 2026-02-26 | — | — | US | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-117083268-B | Amino heteroaryl compounds and compositions | 安锐生物医药科技(广州)有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4308556-A1 | AMINO HETEROARYL COMPOUNDS AND COMPOSITIONS | Anrui Biomedical Technology (Guangzhou) Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-117083268-A | Amino heteroaryl compounds and compositions | 安锐生物医药科技(广州)有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023213308-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 苏州隆博泰药业有限公司 | 2023-11-09 | — | — | WO | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022193499-A1 | AMINO HETEROARYL COMPOUNDS AND COMPOSITIONS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | NPC1 4269/4885RAB9A 2745/4885ALDH1A1 4805/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | NPC1 4269/4885RAB9A 2745/4885ALDH1A1 4805/4885 |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, CSNK2A3, CSNK2B | NPC1 4125/4885RAB9A 3995/4885ALDH1A1 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.